PIK3CA Mutations in HR+, HER2- Metastatic Breast Cancer

Uncovering PIK3CA Mutations

Just as your HR and HER2 status tell your doctor whether certain proteins fuel your cancer, your PIK3CA mutation status tells your doctor more about your cancer, including how else it may grow. If you have HR+, HER2- metastatic breast cancer (mBC) and test positive for a PIK3CA mutation, your doctor can discuss whether PIQRAY® (alpelisib) tablets could be an appropriate treatment option for you. 


About PIK3CA Mutations

If your mBC contains a PIK3CA mutation, that means you have an abnormal, or mutated, PIK3CA gene. An abnormal PIK3CA gene can create proteins that may cause cancer cells to grow and spread. PIK3CA is the most common mutation that affects people with HR+, HER2- breast cancer.

To determine your PIK3CA status, your doctor will test your cancer.

PIK3CA Mutation Testing

Your health care provider will have your cancer analyzed and searched for a PIK3CA mutation.


If you have a PIK3CA mutation, ask your doctor about PIQRAY and what it could mean for your course of treatment.